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ABSTRACT
Objective: The aim of this review was to evaluate the scientific evidence supporting the hypo-
thesis that male circumcision reduces the risk of HIV infection and consequently the incidence of 
acquired immunodeficiency syndrome (AIDS). 
Patients and  Methods: We performed a literature search of the major databases (Medline, 
Embase, Cochrane Library, Biosis and Science Citation Index) for papers published in the period 
1999 to 2008, using the terms “male circumcision”, “HIV infection” and “sexually transmitted 
infection,” plus the combination of the search terms “foreskin” and “HIV receptor” to identify 
1,048 articles. We reviewed the abstracts to identify 278 articles meriting detailed review. This 
detailed review considered how well individual studies were designed and carried out, using 
a standard checklist to provide a systematic quality rating for individual studies. This process 
identified a total of 80 papers, which were rated following the level of evidence and grade of 
recommendation scales modified from the Oxford Center for Evidence-Based Medicine.
Results:  Detailed analysis of the selected articles on male circumcision and HIV infection risk 
revealed the following. Systematic reviews, meta-analyses and modeling studies: there were 11 
papers, 10 positive (favoring circumcision) and 1 negative; of the 10 positive studies, 4 were level 
3 evidence, 5 were level 2 and 1 was level 1 evidence. Randomized controlled trials: there were 
3 studies, all positive with level 1 evidence. Non-randomized cohort studies: there were 6 papers, 
5 were positive (2 level 3 and 3 level 2 evidence) and 1 was negative (level 3 evidence). Case-
control studies: there were 12 studies, 11 positive (all level 3) and 1 negative (level 3 evidence). 
Case series: there were 2 studies, both positive (level 3 evidence). Expert opinion: there were 
34 studies, 30 positive (15 level 4, 15 level 3 evidence), 2 negative (both level 4) and 2 neutral 
(both level 4 evidence). Cost-effectiveness studies: there were 3 studies, all positive, all level 
2 evidence. Pertinent biological studies: there were 3 studies, all positive, all level 4 evidence. 
The three large, exceptionally well-done randomized, controlled trials of adult male circumcision 
among consenting, healthy men in three African countries enrolled a total of 10,908 uncircumcised, 
HIV-negative adult men. The cumulative HIV infection risk estimated using intention-to-treat 
Kaplan-Meier analysis showed an overall rate ratio (RR) of 0.42 (95% confidence interval (CI) 
0.31-0.57), corresponding to a protective effect of 58% (95% CI 43-69%). Meta-analysis of the 
“as-treated” results of the three trials showed even stronger protection against HIV infection in the 
circumcision group (summary RR 0.35, 95% CI 0.24-0.54).
Conclusions: Rigorous analysis of the available scientific evidence clearly supports a positive 
recommendation that male circumcision should be actively promoted in populations at high 
risk of HIV infection. There is a need to provide safe male circumcision services for high-risk 
populations, because this is one of very few proven HIV prevention strategies. Male circumcision 
provides a much-needed addition to the limited HIV prevention armamentarium. The challenges 
to implementation must now be faced.
Keywords : male circumcision, HIV/AIDS
Corresponding Author:  C. F. Heyns, Department of Urology, PO Box 19063, Tygerberg 7505, South Africa, 
e-mail:cfh2@sun.ac.za
Article Info: Date received: 12/9/2008                                 Date accepted : 13/9/2008 
77
MALE CIRCUMCISION AND HIV/AIDS RISK – ANALYSIS OF THE SCIENTIFIC EVIDENCE
HIV/AIDS transmission has not been laid to 
rest completely. 
The aim  of this review  was to evaluate the 
scientific evidence supporting the hypothesis 
that male circumcision reduces the risk of 
HIV infection and consequently the incidence 
of AIDS.
PATIENTS AND METHODS                                     
We  performed a literature search for 
papers published or accepted for publication 
in peer reviewed journals, and excluded 
papers published in non-peer reviewed 
supplements. The search included the last 
10 years of data in the major databases 
(Medline, Embase, Cochrane Library, Biosis, 
and Science Citation Index). 
For inclusion in the final analysis, 
we required papers that either contained 
original data or original data analyses, such 
as systematic reviews or meta-analyses. We 
also included relevant articles on possible 
biological mechanisms and articles that 
reviewed selected data and opinions. 
The search strategy used the term “male 
circumcision” combined with the terms “HIV 
infection,” “complications,” “acceptability,” 
and “sexually transmitted infection,” plus the 
combination of the search terms “foreskin” 
and “HIV receptor” to identify 1,048 
articles.
Included papers were rated according to 
levels of evidence. The hierarchy of study 
types was: systematic reviews and meta-
analysis or modeling, randomized controlled 
trials, non-randomized cohort studies, case-
control studies, case series, and expert opinion 
(as the lowest level). In addition, we included 
other relevant biological studies and cost-
effectiveness studies. We reviewed the titles 
and abstracts of the articles identified in the 
initial search to identify 278 articles meriting 
detailed review. 
INTRODUCTION                                                    
During the past two decades there has 
been considerable controversy regarding the 
question whether male circumcision reduces 
the risk of human immunodeficiency virus 
type 1 (HIV) infection and, consequently, the 
incidence of the acquired immunodeficiency 
syndrome (AIDS). 
An increased risk of uncircumcised men 
acquiring HIV or other sexually transmitted 
infections (STIs) may be explained by a 
number of plausible biological mechanisms. 
These include an increased rate of 
inflammatory conditions, susceptibility of 
the mucosal surface of the prepuce to trauma, 
and the longer survival of pathogens in the 
warm, moist subpreputial space. The lack of 
keratinization and the high density of HIV 
target cells make the inner foreskin especially 
susceptible to HIV infection, compared with 
the keratinized surface of the outer foreskin 
and glans1-4.
The possibility that male circumcision 
may protect against HIV infection was first 
suggested in 19865. Ecological studies in areas 
with low prevalence of male circumcision 
and high HIV prevalence in sub-Saharan 
Africa and in developing countries elsewhere 
have supported this hypothesis6,7. Further 
evidence comes from systematic reviews 
of observational study data comparing 
HIV infection rates in circumcised and 
uncircumcised men1,8. A meta-analysis of 15 
studies adjusted for potential confounders 
found the reduced risk of HIV infection 
in circumcised men to be large and highly 
significant (adjusted risk ratio (RR) 0.42, 
95% confidence interval (CI) 0.34-0.54)1. 
Subsequent studies have reported similar 
findings9. 
Three randomized clinical trials of 
adult male circumcision in South Africa, 
Kenya, and Uganda have reported highly 
significant decreases in HIV infection risk 
among participants randomly assigned 
to circumcision10-12. Nonetheless, the 
controversy about male circumcision and 
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This detailed review considered how well 
individual studies were designed and carried 
out using a standard checklist to assure 
that a consistent approach was used in the 
methodological assessment of the evidence. 
The objective of the checklist was to provide 
a systematic quality rating for individual 
studies. This process identified a total of 
80 papers, representing every study type 
category.
Papers were rated following the level of 
evidence scale modified from the Oxford 
Center for Evidence-Based Medicine (http://
minerva.minervation. com/cebm /docs/ levels. 
html.) Levels of evidence were assigned as 
either positive (circumcision reduces HIV 
infection risk) or negative (circumcision does 
not reduce HIV infection risk). A level of 
evidence was given to each individual study. 
Level 1 evidence: -  meta-analysis of 
randomized controlled trials (RCTs) or a 
good quality RCT, or ‘all or none’ studies 
in which no treatment is not an option. 
Level 2 evidence: -  “low quality” RCTs 
(e.g. < 80% follow-up) or meta-analysis 
(with homogeneity) of good quality 
prospective ‘cohort studies’. 
Level 3 evidence: -  good quality 
retrospective ‘case-control studies’ or 
good quality ‘case series’, or high-quality 
systematic reviews of available data that 
did not incorporate meta-analyses or 
evaluation of the original data.
Level 4 evidence: -  expert opinion where 
the opinion is based not on evidence but 
on ‘first principles’ (e.g. physiological or 
anatomical) or bench research. 
As with levels of evidence, the grades of 
recommendation may apply either positively 
(do the procedure) or negatively (do not 
do the procedure). There are four grades of 
recommendation.
Grade A recommendation -  usually de-
pends on consistent level 1 evidence and 
often means that the recommendation is 
Table 1: Summary of randomized controlled clinical trials of male circumcision to prevent HIV infection in three African countries.










Age range (years) 18-24 18-24 15-49
Setting Peri-urban Urban Rural
Circumcision method Forceps-guided by local 
general practitioners, 
Monopolar cautery
Forceps-guided by study 
clinicians,
No cautery
Sleeve method by study 
clinicians
Bipolar cautery
Visit schedule (months) 3, 12 and 21 1, 3, 6, 12. 18 and 24 6, 12 and 24
Retention rate 92% at 21 months 86% at 24 months 90% at 24 months
Person-years of follow-up 4,693 4,428 6,744
HIV infections (circumcision:control) 20:49 19:46 22:45
Risk ratio (95% CI) 0.41 (0.24-0.69) 0.41 (0.24-0.70) 0.43 (0.24-0.75)
Summary risk ratio for all three trials 
(95% CI)
0.42 (0.31-0.57)
CI = confidence interval.  Modified from Weiss, et al.9
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effectively mandatory and placed within 
a clinical care pathway. However, there 
will be occasions where excellent evi-
dence (level 1) does not lead to a Grade 
A recommendation, for example, if the 
therapy is prohibitively expensive, dan-
gerous or unethical. 
Grade B recommendation -  usually de-
pends on consistent level 2 and/or 3 stu-
dies, or ‘majority evidence’ from rando-
mized clinical trials (RCT’s). 
Grade C recommendation -  usually 
depends on level 4 studies or ‘majority 
evidence’ from level 2/3 studies. 
Grade D (“no recommendation  -
possible”) is used where the evidence 
is inadequate or conflicting and when 
expert opinion is delivered without a 
formal analytical process. 
RESULTS                                                        
Detailed  review  and  analysis of 
the selected articles on studies of male 
circumcision and HIV infection risk in the 
period 1999 to 2008 revealed the following. 
Systematic reviews, meta-analyses  -
and modeling studies1,7-9,13-20: There 
were 11 papers, 10 positive (favoring 
circumcision) and 1 negative; of the 10 
positive studies, 4 were level 3 evidence, 5 
were level 2 and 1 was level 1 evidence.  
Randomized controlled trials - 10-12: The-
re were 3 studies, all positive with level 
1 evidence. 
Non-randomized cohort studies - 21-26: 
There were 6 papers, 5 were positive (2 
level 3 and 3 level 2 evidence) and 1 was 
negative (level 3 evidence). 
Case-control studies - 27-39: There were 12 
studies, 11 positive (all level 3) and 1 ne-
gative (level 3 evidence). 
Case series - 40-41: There were 2 studies, 
both positive (level 3 evidence). 
Expert opinion - 6,42-76: There were 34 
studies, 30 positive (15 level 4, 15 level 3 
evidence), 2 negative (both level 4) and 2 
neutral (both level 4 evidence). 
Cost-effectiveness studies - 77-79: There 
were 3 studies, all positive, all level 2 
evidence. 
Pertinent biological studies - 2-4: There 
were 3 studies, all positive, all level 4 
evidence. 
Therefore, during the last 10 years, the 
great preponderance of evidence, at all four 
levels, has been positive, i.e. supporting the 
hypothesis that male circumcision reduces 
the risk of HIV infection.
The three large, exceptionally well-
done RCTs of adult male circumcision 
among consenting, healthy men in three 
African countries enrolled a total of 10,908 
uncircumcised, HIV-negative adult men10-
12. Participants were randomly assigned to 
circumcision or control arms, then followed 
for up to 2 years. Retention rates were high 
(86-92%). 
Table 1 shows the cumulative HIV infection 
risk among men estimated using intention-to-
treat Kaplan-Meier analysis. The overall rate 
ratio (RR) was 0.42 (95% confidence interval 
(CI) 0.31-0.57), corresponding to a protective 
effect of 58% (95% CI 43-69%). 
The true protection provided by male 
circumcision may be better estimated by an 
“as-treated” analysis, assigning outcomes 
according to the actual circumcision status of 
participants. All participants did not adhere 
to the arm they were randomly assigned to. 
Meta-analysis of the “as-treated” results of 
the three trials shows even stronger protection 
against HIV infection in the circumcision 
group (summary RR 0.35, 95% CI 0.24-
0.54)9.
DISCUSSION                                                       
While observational studies showing a 
statistically significant risk of HIV infection 
among circumcised men provide provocative 
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and compelling evidence, they cannot prove 
causality. However, the three randomized, 
controlled clinical trials of adult male circum-
cision conducted in South Africa, Kenya and 
Uganda do provide compelling evidence that 
circumcision substantially reduces the risk of 
female-to-male HIV transmission10-12. 
Comparing the adverse event rates in 
the three RCTs is complicated because the 
studies had different visit schedules, adverse 
event definitions and criteria. In the Kenyan 
trial, adverse events possibly, probably or 
definitely related to circumcision occurred 
in 23 of 1334 circumcised participants 
(1.7%)80-81. All adverse events were mild or 
moderate and resolved quickly. In the South 
African trial, the adverse event rate was 54 
per 1495 (3.6%) men10. In the Ugandan trial, 
the surgery-related adverse event rate was 
7.6% (178/2328)12. The risk of moderate 
adverse events related to surgery was 3% 
in the Uganda trial, including five severe 
adverse events (0.2%). All of these events 
were managed successfully. 
Detailed analyses of the African trials 
indicate that male circumcision is likely to 
be very cost-effective77. The South African 
trial estimated that the cost per HIV infection 
averted was about US$ 181, with net savings 
of US$ 2.4 million over 20 years (cost 
savings of US$ 2,631 per circumcision). The 
Kenyan trial estimated the cost as $200 per 
HIV infection averted9. Costs were higher in 
Uganda, where 39 circumcisions would be 
needed to prevent one HIV infection over 10 
years at a cost of US$ 2,631 per HIV infection 
averted over 10 years78. Because benefits of 
circumcision are life-long, male circumcision 
is likely to prove very cost-effective in high-
risk African settings.
Several controversial issues remain, 
including the cultural acceptability of male 
circumcision in non-circumcising African 
communities, socio-cultural and economic 
issues of expanding male circumcision 
services, and the relevance of the findings for 
other populations. 
The RCT data indicate that adult male 
circumcision can be safe in limited-resource 
settings when performed by experienced, 
well-trained providers. However, when 
male circumcision is undertaken in septic 
conditions by inexperienced providers or with 
poor aftercare, serious complications or even 
death can result. Thus, implementation of 
safe adult male circumcision in many African 
settings will require considerable effort and 
national policies.
The potential for an increase in unsafe sex 
practices (known as, ‘risk compensation’ or 
‘behavioral disinhibition’) after circumcision 
could potentially offset the protective effect of 
male circumcision. The Ugandan trial found 
no difference in sexual behaviors during 
the trial by circumcision status12. The South 
African trial showed a significantly increased 
mean number of sex acts between 4 and 21 
months among men in the circumcision 
arm, but no increase in the number of sexual 
partners or a change in condom use10. The 
Kenyan trial reported a decrease in reported 
risk-taking behaviors during the 24 months of 
follow-up in both study arms11. 
The RCT findings are reassuring, but 
these data may not be generalizable. The 
trials provided the highest standards of 
preventative care, with intensive individual 
counseling. Furthermore, participants did not 
know that circumcision reduced their risk of 
HIV infection. The challenges of expanding 
services within already overstretched health 
systems include the need to provide adequate 
counseling to convey the message that male 
circumcision is a risk-reduction strategy that 
provides partial protection only.
Nevertheless, the positive findings in 
the male circumcision RCTs are in stark 
contrast to recent negative reports of other 
HIV prevention interventions, including: 
microbicides, the female diaphragm and gel, 
treatment to suppress genital herpes infections 
and, most recently, an adenovirus-based HIV 
vaccine. 
In conclusion rigorous analysis of the 
available scientific evidence clearly supports 
a Grade A positive recommendation that 
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male circumcision should be actively 
promoted in populations at high risk of HIV 
infection. There is a need to provide safe 
male circumcision services for high-risk 
populations, because this is one of very few 
proven HIV prevention strategies. In addition 
to other health benefits, male circumcision 
provides a much-needed addition to the 
limited HIV prevention armamentarium. The 
challenges to implementation must now be 
faced.
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